MedTrace Logo

Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease

NCT04857606 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2023-11-07

No results posted yet for this study

Summary

This study aims to assess the safety and tolerability of AMG 609 when administered subcutaneously as single doses in participants with non-alcoholic fatty liver disease (NAFLD).

Conditions

  • Non-alcoholic Fatty Liver Disease

Interventions

DRUG

AMG 609

Single dose of AMG 609 administered as a subcutaneous injection.

DRUG

Placebo

Single dose of placebo administered as a subcutaneous injection.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-24
Primary Completion
2023-07-19
Completion
2023-07-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04857606 on ClinicalTrials.gov